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Background: Long non-coding RNAs (lncRNAs) are a sub-class within non-coding RNA repertoire that have
emerged as crucial regulators of the gene expression in various pathophysiological conditions. lncRNAs display
remarkable versatility and wield their functions through interactions with RNA, DNA, or proteins. Accumulating
body of evidence based on multitude studies has highlighted the role of lncRNAs in many autoimmune and
inflammatory diseases, including type 1 diabetes (T1D).
Main body of abstract: This review highlights emerging roles of lncRNAs in immune and islet β cell function
as well as some of the challenges and opportunities in understanding the pathogenesis of T1D and its complications.
Conclusion: We accentuate that the lncRNAs within T1D-loci regions in consort with regulatory variants and enhancer
clusters orchestrate the chromatin remodeling in β cells and thereby act as cis/trans-regulatory determinants of
islet cell transcriptional programs.
Keywords: Long non-coding RNAs, Type 1 diabetes, Enhancers, Regulatory elements, 3D genome architectureBackground
Type 1 diabetes (T1D) is a chronic immune-mediated
disease resulting from selective destruction of insulin-
producing pancreatic islet β cells. A complex interplay
between several environmental and genetic risk factors
contribute to the onset of T1D [1, 2]. Defects in both
immune system and β cells play an active role in T1D
pathogenesis [3]. In recent years, efforts have been acce-
lerated to gain insights into the molecular mechanisms of
pathogenesis of T1D and to determine how genetic loci
contribute to the T1D risk [1, 4]. Based on genome-wide
association studies (GWAS), currently more than 50 ge-
nomic risk loci have been identified for T1D [2, 5–7]. Ap-
proximately, 50% of the genetic risk for T1D is known to
reside within the human leukocyte antigen (HLA) region;
however, other non-HLA disease susceptibility loci have
been identified based on their direct influence on the risk.
Some of the well-established candidate genes in the non-
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(10p15), and IFIH1 (2q24) have been associated with
immune response, insulin expression, and β cell function
[1, 4, 8]. The risk alleles for several T1D susceptibility
genes are not exclusively confined to T1D but have been
shown to confer risk in other prevalent autoimmune dis-
orders, including multiple sclerosis (MS), systemic lupus
erythematosus (SLE), and rheumatoid arthritis (RA) [7].
Furthermore, most of these risk variants are located in
non-coding genomic regions including long non-coding
RNAs (lncRNAs) and are enriched in distal regulatory ele-
ments such as enhancers and promoters. Non-coding va-
riants affecting regulatory elements have the potential to
perturb chromatin folding leading to mis-expression of
the target gene. These facts suggest that the regulatory
landscape of human genome plays an important role in
pathology of a disease and newer approaches are needed
to identify putative regulatory risk variants affecting gene
regulation and immune function.
Recent advances in our understanding of lncRNA bio-
logy has offered new perspectives on gene regulation and
has allowed us to unveil the regulatory potential of these
versatile molecules in a spectrum of biological processes
and pathologies, including autoimmune and inflammatory
disorders. High-throughput technologies such as ChIP-le is distributed under the terms of the Creative Commons Attribution 4.0
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have also opened new possibilities to investigate in detail
potential regulatory roles of non-coding genome in gene
regulation and 3D chromatin folding. In this review, we
discuss the recent discoveries in the field of lncRNAs,
regulatory elements, 3D genome architecture, and their
implications for T1D and β cell function. We further high-
light the role of active enhancers associated with T1D–loci
lncRNAs and protein-coding genes in regulating β cell
gene expression programs through both cis- and trans-
regulatory mechanisms involving structural remodeling of
chromatin in human islets.
Main text
lncRNAs in T1D and other immune-mediated diseases
lncRNAs are non-coding RNAs that are more than 200
nucleotides in length, and are capped, polyadenylated, and
spliced like their well-characterized “cousins,” protein-
coding transcripts, with one exception; lncRNAs do not
code for proteins [9]. Most of the lncRNAs are expressed
in a cell-specific manner and are usually expressed in
lower abundance than the protein-coding transcripts. In
terms of genomic location, lncRNAs have been often cate-
gorized as long intergenic non-coding RNAs (lincRNAs),
intronic lncRNAs, antisense lncRNAs, divergent lncRNAs
and enhancer-derived lncRNAs (lncRNAs arising from
enhancer-like regions) [10–12] (Fig. 1). lncRNAs haveFig. 1 Bio-types of lncRNAs and enhancer-derived lncRNA function. a Diffe
antisense, intergenic, intronic, divergent and enhancer-derived lncRNAs. lnc
green. b The postulated role of enhancer-derived lncRNAs for both cis- and
loop formation. Figure modified from Ref. [10, 11]emerged as important players of gene regulation and
have been implicated in various human pathologies
[13]. lncRNAs regulate various cellular and biological
processes including heterochromatin formation, histone
modifications, DNA methylation targeting, and gene
silencing [14, 15]. The lncRNA-recruited regulatory
complexes orchestrate development and differentiation
of various immune cell lineages and actively regulate
expression programs within these cells.
Multiple studies have highlighted the potential roles
of lncRNAs in pancreatic islets and T1D pathogenesis
[10, 16, 17]. Based on transcriptome profiling studies of
islets and β cells, more than 1000 islet-specific lncRNAs
have been identified in both human and mouse islets
[18, 19]. The ability of lncRNAs to regulate gene
expression and cell-specific identity provides an exci-
ting opportunity to advance our understanding of T1D
pathogenesis. Table 1 lists examples of lncRNAs that
have been implicated in β cell function and T1D.
lncRNA MALAT1 has been associated with diabetes-
induced microvascular dysfunction in STZ-induced
diabetic rats and db/db mice [20]. Knockdown ofMALAT1
prevents the hyper-proliferation of retinal endothelial cells
through p38 MAPK signaling and might serve as a poten-
tial target for anti-angiogenic therapy for diabetic retino-
pathy. lncRNA MEG3 has been associated with paternally
inherited risk of T1D [21] and its downregulation affectsrent bio-types of lncRNAs based on their genomic location include
RNAs are depicted in blue, while protein-coding genes are shown in
trans-mediated regulation of target genes is shown via chromatin
Table 1 lncRNAs associated with β cell function and type 1
diabetes
lncRNAs Function Reference
MEG3 Regulates β cell identity and function
via insulin production and apoptosis
in mouse MIN6 cells and isolated
mouse islets
You et al.
2016 [22]
HI-LNC25 Positively regulates GLIS3 (which
contains both T1D and T2D risk
variants) in EndoC-βH1 human β
cell line
Moran et al.
2012 [18]
βlinc1
(HI-LNC15)
Regulates β cell identity and function
in mouse MIN6 cells and EndoC-βH1
human β cell line; also regulates its
neighboring gene NKX2.2 (an islet
transcription factor).
Arnes et al.
2016 [23]
TUNAR
(HI-LNC78)
Knockdown of TUNAR leads to
impaired glucose-stimulated insulin
secretion in human islets
Akerman
et al.
2017 [24]
PLUT
(HI-LNC71)
Regulates transcription of PDX1, a
key pancreatic β cell transcriptional
regulator, in EndoC-βH1 cells,
primary islet cells, mouse β cell
line MIN6
Akerman
et al.
2017 [24]
MALAT1 Upregulation of MALAT1 is associated
with microvascular dysfunction
(diabetic retinopathy) in STZ-induced
diabetic rats and db/db mice
Liu et al.
2014 [20]
TUG1 Downregulation of lncRNA TUG1
expression increased apoptosis and
reduced insulin secretion in mouse
β cells
Yin et al.
2015 [25]
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knockdown of trans-acting islet-specific lncRNA HI-
LNC25 (LINC01370) in mature β cells resulted in down-
regulation of GLIS3 gene [18]. GLIS3 encodes an islet
transcription factor (TF) and is a candidate gene for both
type 1 and type 2 diabetes. Another islet-specific lncRNA
βlinc1 (previously known as HI-LNC15) has been shown
to be essential for proper specification and function of β
cells [23]. Knockdown of βlinc1 in mouse MIN6 cells and
human insulin-producing EndoC-βH1 cells resulted in
downregulation of several islet-specific TFs, including
Nkx2.2, Pax6, and Mafb [23]. Also, deletion of βlinc1 re-
sulted in defective islet development and disrupted glucose
homeostasis in the adult mice [23]. It is particularly intri-
guing that βlinc1 specifically regulates three essential islet
TFs (Nkx2.2, Pax6, and MafB) and additional β cell genes
on chromosome 2, all of which are associated with endo-
crine development and maintaining islet morphology [23].
Nuclear-enriched β cell lncRNA PLUTO (PLUT) (pre-
viously known as HI-LNC71) regulates the transcription of
PDX1 gene which is a key pancreatic β cell transcriptional
regulator [24]. PLUT encompasses a cluster of enhancers
that make 3D contacts with the PDX1 promoter in human
islets and in human β cell line EndoC-βH1. Loss of PLUT
was associated with downregulation of PDX1 at bothmRNA and protein levels in EndoC-βH1 cells, primary
islet cells, and a similar effect was observed for the mouse
lncRNA ortholog in mouse β cell line MIN6 [24]. Knock-
down of lncRNA TUNAR (HI-LNC78) resulted in reduced
insulin content and impaired glucose-stimulated insulin
secretion in T antigen-excised EndoC-βH3 cells [24].
lncRNA TUG1 is a highly conserved lncRNA in mam-
mals and is highly expressed in mouse pancreatic
tissues [25]. In mouse β cells, downregulation of TUG1
as a consequence of hyperglycemia resulted in in-
creased apoptosis and reduced insulin synthesis and
secretion [25]. These findings suggest that TUG1 may
partially contribute to the impairment of β cell function
and could therefore be implicated in diabetes pathogenesis.
In recent years, growing body of evidence has linked
dysregulation of lncRNA expression to a spectrum of
autoimmune disease [26, 27]. Hrdlickova and colleagues
found enrichment of lincRNAs in autoimmune disease-
associated loci in a subset of immune cells [28]. A num-
ber of studies describe the emerging role of lncRNAs
in transcriptional regulation of inflammatory gene ex-
pression [29, 30]. For example, in human monocytes,
lncRNA THRIL has been shown to interact with
hnRNP-L and regulate the expression of TNFα [31].
Correspondingly, additional examples of lncRNAs in-
volvement in inflammatory signaling cascades and
regulation of innate immune responses includes (1)
lncRNA PACER (PACERR) which has been shown to
bind p50 subunit of NFκB and control the basal ex-
pression levels of Cox2 (PTGS2) [32]; (2) in primary
human monocytes, knockdown of NFκB regulated,
enhancer-RNA (eRNA) IL1β-eRNA and region of bi-
directional transcription (RBT) IL1β-RBT46, mitigated
bacterial lipopolysaccharide (LPS) pro-inflammatory
cytokine IL1β induction and release [33]; (3) overexpres-
sion of natural antisense transcript anti-IL1β alters the
chromatin structure around the IL1β promoter and conse-
quently inhibits the IL1β expression [34, 35]. In a murine
model, lncRNA NeST (Nettoie Salmonella pas Theiler’s;
cleanup Salmonella not Theiler’s) was shown to epigeneti-
cally regulate the interferon-γ (IFN-γ) locus and control
the susceptibility to Theiler’s virus and Salmonella in-
fection [36, 37]. Together, these findings indicate that
lncRNAs play etiological role in autoimmune diseases.
lncRNAs have also been shown to play pivotal roles in the
Toll-like receptor (TLR) signaling pathway. For example,
when macrophages and dendritic cells (DCs) were stimu-
lated with TLR ligands, the lincRNA-Cox2A was found to
be highly inducible and also controlled the basal expres-
sion levels of interferon-stimulated genes (ISGs) and pro-
inflammatory cytokines [29]. Intriguingly, pseudogenes
lncRNAs have been identified to act as functional regula-
tors of inflammatory signaling with their expression being
actively regulated. Stimulation of mouse embryonic
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sion of lncRNAs. Lethe, a pseudogene lncRNA, has been
shown to function as a novel negative regulator of NF-κB.
Lethe, wields its regulatory function by binding directly
RelA, a subunit of NF-κB heterodimeric complex, pre-
clude NF-κB binding to the promoter regions of target
genes [38]. Another pseudogene lncRNA Lnc-dendritic
cell (DC) (WFDC21P) has been shown to be involved in
monocyte to DC differentiation [39].
Systemic cell-mediated immunity is known to play a
central role in the apoptotic β cell destruction that culmi-
nates in T1D. The T helper 17 (Th17) cells are known to
protect mucosal barriers from opportunistic infections
and are also associated with number of autoimmune
inflammatory diseases. Like many other autoimmune dis-
eases, T1D is also a T cell-mediated malady, and imba-
lance between the Th17 cells and T regulatory (Treg) has
been implicated in development of the T1D [40, 41].
Recently, Huang et al. [42] demonstrated role of DEAD-
box protein 5 (DDX5) as a binding partner of RORγt, a
well-known ligand-regulated nuclear receptor that con-
trols the differentiation of Th17 cells. Interestingly, DDX5
coordinates the transcription of selective Th17 genes
through its interaction with RORγt, and it is also required
for Th17 cell-mediated inflammatory diseases. The inte-
raction between DDX5 and RORγt is dependent on the
inherent RNA helicase activity of DDX5 and the binding
of Rmrp, an evolutionarily conserved nuclear lncRNA.
Furthermore, Rmrp was found mutated in patients with
cartilage-hair hypoplasia, and corresponding mutation in
Rmrp in mice resulted in altered chromatin interaction,
and diminished interaction between the DDX5 and
RORγt, and also downregulated expression of selective
Th-17 genes [42].
These examples highlight the importance of lncRNAs
in regulating gene expression in immune cells and
underscore yet another layer of complexity in gene re-
gulation. Future studies should be focused towards elu-
cidating their molecular functions which in turn could
provide crucial insights into novel mechanisms of gene
regulation, autoimmune and inflammation-mediated dis-
orders, including T1D.
Genome-wide interactions between T1D SNPs, lncRNAs,
enhancers, and other distal regulatory elements
More than 90% of disease-associated single-nucleotide
polymorphisms (SNPs) are located within the non-coding
regions of the genome such as promoters, enhancers,
intergenic regions, and ncRNA genes [43]. The disease-
associated SNPs have the potential to be regulatory in
nature, particularly if they are significantly enriched in
functional regulatory elements such as transcription factor
binding sites (TFBSs), histone modification marks,
DNase-I hypersensitive sites, and expression quantitativetrait loci (eQTLs) [44, 45]. These disease-associated
regulatory SNPs are also referred to as “functional SNPs”
[44]. Approximately, 10% of the autoimmune disease-
associated SNPs are present within lncRNAs and some
of these SNPs are also known to act as cis-eQTLs [46].
It has been shown that 75% of the lincRNA cis-eQTLs
specifically alter the expression of lincRNAs in a tissue-
dependent fashion but does not affect the nearby
protein-coding genes, and many of these cis-eQTLs
SNPs are known to be associated with complex genetic
diseases [47]. Since the expression of protein-coding
genes can be regulated by lincRNAs either in cis [48] or
trans [49] manner, this suggests a link between disease-
associated SNPs within the non-coding regions with the
regulation of protein-coding gene expression.
Distal regulatory elements such as enhancers, locus
control regions (LCRs), and insulators are highly abun-
dant in the human genome and play an important role
in transcriptional control. These elements represent the
primary mechanism by which cell and developmental
specific gene expression is accomplished. Enhancers are
regulatory sequences that can activate gene expression
independent of their proximity to their target genes in a
tissue-specific manner [50]. Multiple enhancer elements
arrayed over large regions can synergistically regulate
the expression of individual genes or gene clusters by al-
tering the TF binding and chromatin states [51, 52].
Additionally, multiple polymorphisms in linkage disequi-
librium (LD) impact clusters of enhancer elements active
in the same cell type and cooperatively contribute to al-
tered expression of their gene targets [53]. The multiple
enhancer variants within a given locus typically target
the same gene which results in either gain- or loss-of-
function [53]. Additionally, the genes associated with
multiple enhancer variants encode proteins that are
often functionally related and enriched in common path-
ways. Recently, several methods have been developed for
genome-wide prediction of enhancers primarily based on
chromatin marks such as H3K4 monomethyl (H3K4me1)
and H3K27 acetyl (H3K27ac) modifications, bi-directional
transcription, and binding of p300 [54–57]. The underlying
mechanism for enhancer function has been suggested to
involve formation of long-range chromatin loops, bringing
enhancers and promoters into proximity and allowing
interaction of the necessary co-transcriptional factors
[58, 59]. Formation of chromatin loops occurs between
two distant genomic sequences that are brought in
close vicinity by protein complexes and are assumed to
be chemically cross-linked. Various chromosomal con-
formation capture techniques such as 3C (chromosome
conformation capture) [60], 4C (circular chromosome
conformation capture) [61], 5C (chromosome conform-
ation capture carbon copy) [62], ChIA-PET (Chromatin
Interaction Analysis with Paired-End-Tag sequencing)
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wide chromosome interactions. Examples of long-range
interactions within mammalian gene loci include the
locus control region (LCR) and β-globin promoter [65, 66];
the α-globin gene cluster in erythroid cells [67]; the TH2
and MHC loci in T cells [68, 69]; and the imprinted gene
clusters Dlx5, Dlx6 [70], and H19-Igf2 [71–73]. Additional
example of long-range chromatin loop mediated inter-
action among regulatory elements on different chromo-
somes has been observed at the IFNγ and TH2 cytokine
loci [74]. The transcriptional regulation of IL-21 gene at
the chromatin level was recently uncovered to be mediated
through long-range chromatin interaction in CD4+ T cells.
IL-21, a pro-inflammatory cytokine with pleiotropic effects,
is strongly associated with autoimmunity and inflammation
and regulates various immune responses. A study by Park
et al. showed that a distal enhancer element within an evo-
lutionary conserved non-coding sequence 49 kb upstream
of the IL-21 can upregulate IL-21 gene expression in a
STAT3- and NFAT-dependent manner [75]. Stimulation of
CD4+ T cells with IL-6 leads to the recruitment of STAT3
to the IL-21 promoter and the distal enhancer region,
bringing them in close spatial proximity. As a consequence,
this long-range interaction between the promoter and dis-
tal enhancer region dependent on IL-6/STAT3 signaling
pathway alters the chromatin configuration dynamically,
and controls the expression of IL-21 in CD4+ T cells [75].
Based on published genome-wide chromosome con-
formational capture datasets from various cell-lines and
T1D associated SNPs we identified physical interactions
between distant regulatory regions in T1D loci. Figure 2
shows an interactive map of T1D loci highlighting the
physical interactions between distal regulatory elements
and potential functional T1D SNP at each locus. T1D risk
SNPs and SNPs in LD (r2 > 0.8, CEU HapMap3 popu-
lation) were selected and scored based on the original
GWAS signal, long range chromosome interactions, over-
lap with chromatin marks, epigenetic modifications and se-
quence motifs from various ENCODE cell lines [2, 76–78].
The top most scoring SNP for each region was inferred as
the most significant functional SNP and selected for plot-
ting along with the most significant distal chromosomal
interaction signal. As an example, in ERBB3 locus, SNP
rs4759229 qualified as the most significant variant.
rs4759229 is in perfect LD with T1D risk SNP rs2292239,
overlaps a known enhancer region and has a long range
interaction signal with an antisense lncRNA AC008079.1
(Ensembl ID: ENSG00000187979) located at USP18 locus
on chromosome 22. In a recent study, we proposed that
the ERBB3 SNP rs2292239 and its proxy SNPs in perfect
LD rs3741499 and rs4759229 are putatively functional
based on the overlapping open chromatin marks, TFBs
and DNase I hypersensitivity peaks [79]. We further
showed that SNP rs4759229 overlaps a known enhancerelement and is in the vicinity of several lncRNA transcripts
overlapping ERBB3 locus. The potential functional T1D
SNPs within known T1D candidate genes such as GLIS3,
ERBB3, CTRB1, CTSH, FUT2, IL27, SKAP2, TNFAIP3 and
PTPN2 had highly significant distal chromosomal interac-
tions including enhancers and lncRNAs that are worthy of
specific laboratory investigations (Fig. 2). Intriguingly, the
impact of interactions between T1D SNPs and enhancer
associated lncRNAs on transcription and ultimately on
T1D risk remains to be seen. Based on the above evidence
we postulate that the T1D SNPs mapping to enhancer as-
sociated lncRNAs could potentially alter the expression of
their gene targets through enhancer mediated interactions
and thereby significantly impact β cell gene expression.
Many lncRNAs have been reported to be expressed
from the enhancer regions that are produced by
activity-dependent RNA polymerase II binding of spe-
cific enhancers [80]. The expression levels of these en-
hancer associated lncRNAs positively correlate with the
expression of neighboring protein-coding genes, i.e.,
depletion of enhancer associated lncRNAs led to de-
creased expression of their neighboring protein-coding
genes [48, 80]. In addition, enhancers overlapping lncRNAs
have higher H3K4me3/H3K4me1 ratios as compared to
enhancers that do not overlap lncRNAs [81]. The en-
richment of H3K4me3 marks (which are also associated
with active promoters) points towards strong transcrip-
tional capabilities of overlapping lncRNAs. lncRNAs tran-
scribed from active enhancers have been identified as
important players in mediating enhancer function [82].
Enhancers associated lncRNA play roles in important
physiological processes and influence the activation of pro-
tein coding and non-coding genes in both cis and trans
mediated mechanism. For example, lncRNA NEST is
involved in cis-activation of the neighboring interferon γ
locus, whereas lncRNA Jpx regulates trans-activation of
another lncRNA, XIST, (which is critical for X inactivation)
[36, 83]. While acting in trans, enhancer associated
lncRNAs act over long distances by long range chromatin
loop mediated interactions and activate transcription at
distal promotors. It has also been suggested that bridging
factors such as Mediator/Cohesin complex and enhancer
associated lncRNAs are involved in establishment of chro-
matin looping between the lncRNAs and their regulated
distal promotors [84]. Knockdown of either lncRNA or
mediator subunits has been shown to abolish the chromo-
somal interactions [84].
It has been shown that islet-specific lncRNAs and
TFs co-regulate genes associated with enhancer clus-
ters [24, 85]. lncRNAs regulating enhancer cluster-
associated genes bound by multiple islet-specific TFs
include HI-LNC12, HI-LNC15, HI-LNC30, HI-LNC78,
HI-LNC80, HI-LNC85, and PLUT (HI-LNC71) [24].
However, further studies are warranted that employ
Fig. 2 Distal regulatory elements and potential functional T1D SNPs in T1D susceptibility loci. The inner circle represents T1D susceptibility genes
and genomic loci and the outer circle lists the regulatory variants and distal interaction regions. The distal interactive elements are denoted by an
asterisk which includes enhancer elements and lncRNAs. The red lines indicate long-range chromosome interaction signals to another locus and
the intensity of interaction is represented by the width of the red lines
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tential targets of enhancer associated lncRNAs in hu-
man islets.
Future challenges and opportunities
Although lncRNAs have achieved formable recognition as
key players in gene regulation and disease, there is still a
huge gap in our overall understanding of lncRNA regula-
tory functions and underlying molecular mechanisms,
particularly in context of β cell function and development
of T1D. The rise of lncRNAs as key regulators of gene
expression during normal development and diseases has
positioned these pervasive transcripts in the crosshairs of
novel disease-specific biomarker discovery. The dysregula-
tion of lncRNA expression not only represents a new-
fangled layer of intricacy in the molecular architecture of
human malady, but it also unveils the potential to use
lncRNAs as disease biomarkers. In contrast to their “cou-
sins” mRNA transcripts, the lncRNAs themselves are
functional molecules and their expression levels might
serve as a better disease indicator. Moreover, expression
of lncRNAs is highly tissue-specific and disease-specific
which indicates that lncRNA-based expression signatures
could effectively be used to accurately diagnose and
classify disease. Although, the field of lncRNA-baseddiagnostics is still in its infancy, the use of distinct
lncRNAs in a clinical diagnostics setting has already taken
off. Indeed, lncRNAs have already been suggested as po-
tential biomarkers for a number of diseases, including
cancer. For example, PCA3, a prostate-specific lncRNA
notably overexpressed in prostate cancer, has been deve-
loped into diagnostic assay to detect prostate cancer [86].
Nevertheless, there are still many challenges ahead of us
that need to be addressed in order to fully appreciate the
function of lncRNAs in islet biology and T1D contexts.
Most of the functionally characterized lncRNAs ex-
hibit modular-domain architecture that arises from their
well-conserved secondary and tertiary structures and is
crucial for their biological functions. This assumes im-
portance as it illustrates the importance of the conserva-
tion at secondary and tertiary structure level rather than
at primary sequence level [87–89]. Therefore, future
studies are needed to identify homologous lncRNAs ta-
king a structure-based evolutionary conservation crite-
rion into consideration rather than relying only on the
primary sequence-based conservation in cellular and
subclinical models of T1D.
Although, a handful of lncRNAs have been functio-
nally characterized, they have certainly emerged as bona
fide players in regulating the gene expression at various
Mirza et al. Human Genomics  (2017) 11:17 Page 7 of 10levels during all the stages of development and disease.
With the advent of next-generation sequencing tech-
nologies, thousands of lncRNA genes have already been
identified and annotated in human and mouse. Accor-
ding to the recent GENCODE v26 (www.gencodegen-
es.org), more than 15,000 and 11,000 lncRNA genes
have already identified in the human and mouse, re-
spectively. In addition, FANTOM5 cap analysis of gene
expression (CAGE) in primary cell types and tissues
identified 27,919 human lncRNA genes with accurate 5′
termini [90]. Based on multiple lines of evidence, inclu-
ding genomic, epigenomic features and evolutionary
conservation of the lncRNAs, 19,175 were reported as
potentially functional in the human genome [90]. Surpri-
singly, most of the intergenic lncRNAs identified in the
FANTOM5 project were transcribed from the enhancers
and not from the promoters.
One of the major bottlenecks in studying the lncRNA
functions has been their low steady-state levels in the cells
[91]. Majority of lncRNAs are expressed at low-levels
which makes it more challenging to accurately annotate
their gene boundaries. The problem of incomplete anno-
tation of lncRNAs is further compounded by the lack of
typical genomic hallmarks of transcription initiation and
termination that are often used as primary flag posts for
defining the gene boundaries [91]. But, recently many
methods have been developed and implemented to im-
prove the annotation of lncRNAs, including RNA Capture
Sequencing (CaptureSeq) [92], coupling of rapid ampli-
fication of cDNA ends (RACE) technique to long-read se-
quencing (RACE-Seq) [93], RNA Capture Long Seq (CLS)
[94], and genome-scale CRISPR-mediated interference
(CRISPRi) [95]. So far, these methods have been used for
exploring the transcriptomic structure of lncRNA loci
using cell or tissue types that are not relevant to diabetes.
Nevertheless, these methods provide an excellent ex-
perimental framework for future studies to address the
lingering questions regarding the roles and molecular
mechanisms of lncRNAs in β cell function and T1D
pathogenesis. Therefore, employing methods like CLS,
RACE-Seq, CAGE and CRISPRi under the proinflamma-
tory cytokines stimulation and control settings will enable
to disentangle the transcriptomic landscape of β cells.
It is known that active β cells exhibit extensive allelic
imbalance in gene expression [96]. However, the impact
of allelic imbalance on the lncRNA expression has been
not studied. A robust reassessment of the regulation of
allele-specific gene expression in lncRNA loci overlap-
ping or lying in close proximity of T1D GWAS SNPs in
islets and β cells derived from cadaveric pancreas with
known genotypes would be highly desirable. This could
provide important clues linking disease-associated SNPs
with the lncRNA expression. Furthermore, these studies
have the potential to unravel the diversity of lncRNArepertoire, including the enhancer RNAs (eRNAs) [97]
and novel rare transcripts and many of which might
have important functional roles in modulating the β cell
function.
Conclusions
In immune-mediated and inflammatory diseases such as
T1D, lncRNA-based transcriptional signatures might open
new avenues for lncRNA-based diagnostics, classification
or personalized therapeutic regimens in near future. Fur-
thermore, assessment of functional implications of T1D
SNPs overlapping lncRNAs and enhancers regions is
highly warranted from perspective of β cell function and
development of T1D. The precise biochemical characte-
ristics and molecular basis of β- and immune cells ex-
pressed lncRNA functions are necessary to elucidate how
deregulations of immune cell-specific T1D loci-associated
lncRNAs, as well islet-specific lncRNAs, potentially con-
tribute to the development of islet autoimmunity to pro-
gression of T1D.
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